Longevity & AgingVideo Summary

Peter Attia Revisits Fasting, Keto, Metformin, Rapamycin and Heavy Lifting After 400 Episodes

After 400 episodes, Peter Attia explains how his views on keto, fasting, metformin, rapamycin, cancer screening and exercise have changed.

Monday, October 12, 2026 8 views
Published in Peter Attia MD
A man in a home gym seated on a bench beside a barbell rack and a stationary bike, thoughtfully looking at a notebook

Summary

In this Ask Me Anything episode, Peter Attia looks back on more than eight years of The Drive and revisits positions he once held firmly. He argues that changing your mind when new evidence, expert conversations, and clinical experience arrive is essential to practicing good medicine. On nutrition, he describes how his thinking on ketogenic diets, extended fasting, and dietary dogmatism has shifted. He explains why he no longer takes metformin for longevity and why he is growing less certain about rapamycin despite strong animal data. He also revisits cancer screening, including whole-body MRI and liquid biopsies. On exercise, he discusses the limits of the 80/20 Zone 2 framework, especially for people short on time, and why he has moved away from heavy barbell squats and deadlifts. The common thread is prioritizing foundations and sustainable habits over marginal optimization.

Detailed Summary

Longevity advice changes quickly, and the people giving it are expected to change with it. In this Ask Me Anything episode, Peter Attia marks 400 episodes of The Drive by revisiting positions he has taken over eight years. He frames the exercise as strong convictions, loosely held: updating beliefs as new evidence, expert conversations, and clinical experience arrive is, in his view, essential to practicing medicine well.

The discussion spans nutrition, drugs, cancer screening, and exercise. On nutrition, Attia describes how his views on ketogenic diets, energy balance, and dietary dogmatism have evolved. He covers extended fasting, including autophagy, lean-mass loss, and who might benefit from prolonged fasts. He also discusses the dietary restriction, time restriction, and calorie restriction framework, and why GLP-1 agonists are tipping the balance toward calorie restriction.

On drugs, he explains that he no longer views metformin as geroprotective for metabolically healthy people and has stopped taking it for longevity. He describes growing uncertainty about rapamycin: the animal data are compelling, but human dosing remains unresolved.

On cancer screening, he stresses the importance of early detection but notes declining whole-body MRI quality and points toward more targeted alternatives. He calls liquid-biopsy technology, including the NHS-Galleri trial, still fuzzy, and argues that detecting early-stage rather than late-stage cancer is what matters.

On exercise, he discusses the limits of the 80/20 Zone 2 framework, how to program cardio at lower training volumes, and how to build a training habit without forcing workouts. He has moved away from heavy barbell squats and deadlifts, favoring alternative exercises and deliberate management of injury risk.

The overarching message is to prioritize principles, foundations, and sustainable practices over marginal optimization. Caveat: this is one clinician's opinion and not a systematic evidence review, and this summary draws only on the episode description.

Key Findings

  • Attia no longer takes metformin for longevity and doesn't view it as geroprotective in metabolically healthy people.
  • His uncertainty about rapamycin is growing: animal data are compelling, but human dosing remains unresolved.
  • GLP-1 agonists are shifting the dietary restriction framework toward calorie restriction, per Attia.
  • He considers liquid-biopsy cancer screening still fuzzy, and says detecting early-stage rather than late-stage cancer is what matters.
  • He has moved away from heavy barbell squats and deadlifts, and sees the 80/20 Zone 2 framework as limited for people with little training time.

Methodology

This is an Ask Me Anything podcast episode in which a physician reflects on how his public positions have changed over 400 episodes. It is expert opinion and clinical experience, not a systematic review or trial. Topics referenced include the NHS-Galleri trial and animal rapamycin data.

Study Limitations

This summary is based on the episode description and abstract only, not the full transcript. The views are one physician's opinions and are not backed by new data presented in the episode. Details of the reasoning behind each change are not available here.

Enjoyed this summary?

Get the latest longevity research delivered to your inbox every week.

Enter your email to subscribe: